Atlas Trials

Dalpicilib-Enhanced Vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer

Clinical trial NCT06637150 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06637150
Sponsor
Fudan University
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Breast Cancer
Start date
2024-09-01
Primary completion
2030-09-30
Enrollment
1388

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.